Jump to page content Accessibility
News, views and contacts from the global Drugdevelopment industry
Login to drugdevelopment-technology.com Log in or Register
  • Home
  • Products & Services
  • Company A - Z
  • Projects
  • Features
  • Videos
  • White Papers
  • News
  • Events
  • Advertise With Us
Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

Prasugrel - Investigational Antiplatelet Agent



The results of the phase III trial showed that treatment with prasugrel was associated with a significantly increased risk of bleeding.


  • Diagram of the heart.

  • A section of an artery showing the formation of an atherosclerotic plaque.

  • Diagrammatic representation of clot formation showing platelets and...
  • The results of the phase III trial of Prasugrel
    The results of the phase III trial showed that treatment with prasugrel was...

  • The results of the phase III trial showed that treatment with prasugrel was...

Back to Project Details



Related Projects

Ariflo (Cilomilast) - Oral PDE-IV Inhibitor for
Ariflo (cilomilast) is an oral selective phosphodiesterase (PDE) IV...

Sativex - Investigational Cannabis-Based treatment for Pain and Multiple Sclerosis
Developed by GW Pharmaceuticals, Sativex is a whole plant medicinal...

Capravirine - Anti-Retroviral Drug
Developed by Pfizer Global Research and Development, capravirine is...

Acomplia (Rimonabant) - Investigational Agent for
Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective...

Tarceva - Small Molecule
Tarceva (erlotinib) is an oral anti-cancer drug developed by...

See all projects


Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2011 Net Resources International, a trading division of SPG Media Limited.